zintick

Altimmune ALT

Altimmune, Inc. · Nasdaq · Pharmaceutical Preparations

$1.61-16.58%close on Nov. 12, 2026 · volume 12.3M · Yahoo Finance

Price, last 58 sessions

$2.00$2.50$3.00Sept. 2026Oct. 2026Nov. 2026
Aug. 24, 2026 to Nov. 12, 2026 · high $3.42 · low $1.61 · SEC filing, placed when SEC released it

Our coverage

Nothing published yet.

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Aug. 13, 2026Jerome Benedict Durso
President and CEO, director
Bought15,000$2.95$44,250

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 18 →
  • 10-QNov. 12, 2026, 4:33 p.m. ETView on SEC.gov
  • 8-KNov. 12, 2026, 7:33 a.m. ETView on SEC.gov

    Results of operations and financial condition · Financial statements and exhibits

    AI summary, unreviewedAltimmune Reports Q3 2026 Net Loss of $0.15 Per Share, a $0.01 Miss Versus $0.14 Consensus, as R&D Spending Rises

  • SCHEDULE 13GNov. 10, 2026, 6:26 a.m. ETView on SEC.gov
  • 4Nov. 4, 2026, 4:04 p.m. ETView on SEC.gov
  • 4Nov. 4, 2026, 4:08 p.m. ETView on SEC.gov
  • 8-KOct. 29, 2026, 7:03 a.m. ETView on SEC.gov

    Creation of a direct financial obligation

    AI summary, unreviewedAltimmune draws $10.0 million Tranche Three under $125.0 million Hercules loan after clinical and financial milestones

  • 8-KOct. 27, 2026, 8:16 a.m. ETView on SEC.gov

    Departure/appointment of directors or officers · Regulation FD disclosure · Financial statements and exhibits

    AI summary, unreviewedAltimmune Adds Two Biotech Veterans Greenleaf and Howarth to Board as Three Directors Retire

  • 4Oct. 5, 2026, 4:10 p.m. ETView on SEC.gov